Search Results

Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced the acquisition of DiscoveryBioMed, a contract research organization (CRO) focused on developing novel human bioassays utilizing cells from diseased and normal human tissues.

Collaboration Will Screen Human Taste Bud Cells with Small Molecule Libraries to Develop Easier Ways for Children and Adults to Take Bitter-Tasting Medications BIRMINGHAM, Ala.--( BUSINESS WIRE )-- DiscoveryBioMed, Inc. (DBM) has been awarded nearly $1.7 million over the next two years by the National Institutes of Health’s Small Business Technology Transfer Research (STTR) program to find bitter taste blockers to improve medication compliance. T

DiscoveryBioMed, Inc . (DBM, www.discoverybiomed.com ) announces a new unit of its contract research organization (CRO) services business called TumorCube that is formed based upon our growing expertise in 3D Biogel-driven bioassays on diseased and normal human cell platform technologies. A trademark application has been filed. “DBM has a growing CRO services business in 3D Biogel-driven bioassays of diseased and